Tumor angiogenesis: Recent progress and remaining challenges;L'angiogenèse tumorale: Progrès récents et défis persistants

Bulletin du Cancer

Volumn 97, Issue 11, 2010, Pages 1305-1310

  Feige, J J ^a  

^a CEA GRENOBLE   (France)

Author keywords

Angiogenesis; Anti angiogenic drug; Dll4; Endothelial cells; Notch pathway; Tumor resistance; VEGF; VEGF receptors

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER SURVIVAL; COLON CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 78650120361     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1208     Document Type: Review

References (27)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 ; 285 : 1182-6.
2. Gimbrone Jr MA, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974 ; 52 : 413-27.
3. Muthukkaruppan V, Auerbach R. Angiogenesis in the mouse cornea. Science 1979 ; 205 : 1416-8.
4. Ferrara N. VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2002 ; 2 : 795-803. (Pubitemid 37328914)
5. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996 ; 380 : 435-9. (Pubitemid 26102719)
6. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996 ; 380 : 439-42. (Pubitemid 26102720)
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004 ; 3 : 391-400. (Pubitemid 38618122)
8. Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biology 2001 ; 11 : S32-S6.
9. Feige JJ. Les facteurs de croissance de l'endothelium vasculaire et leurs récepteurs. In : Robert J, ed. L'Angiogenèse. AMGEN Oncologie-John Libbey Eurotext, 2009.
10. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007 ; 8 : 464-78.
11. Carmeliet P, De Smet F, Loges S, Mazzone M. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009 ; 6 : 315-26.
12. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003 ; 9 : 713-25.
13. David L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008 ; 102 : 914-22. (Pubitemid 351591550)
14. Gaengel K, Genove G, Armulik A, Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 2009 ; 29 : 630-8.
15. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007 ; 109 : 1953-61. (Pubitemid 46348192)
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42. (Pubitemid 38702844)
17. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 ; 357 : 2666-76.
18. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009 ; 27 : 1227-34.
19. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double blind phase III trial. Lancet 2007 ; 370 : 2103-11. (Pubitemid 350296300)
20. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009 ; 27 : 4733-40.
21. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006 ; 3 : 24-40. (Pubitemid 43108832)
22. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005 ; 307 : 58-62. (Pubitemid 40093472)
23. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 2008 ; 8 : 579-91.
24. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009 ; 6 : 569-79.
25. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 2008 ; 105 : 2640-5. (Pubitemid 351520566)
26. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009 ; 15 : 21-34.
27. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009 ; 15 : 7510-8.